Replies to post #270693 on Kraig Biocraft Laboratories Inc (KBLB)

[arachnodude]

It's so hilarious to witness the dilution scare tactics over and over. In reality, an 18-year journey with a relatively modest dilution indicates a long-term commitment to the development of this proprietary, Holy Grail technology and a stable approach to funding. Diluting less than $50 million over such a long period suggests the company has been efficient in its use of capital. No matter how one wants to paint things negatively, this is how those who understand the development will see things with KBLB. This efficiency will signal to them strong operational management and a lean cost structure which speaks volumes once revenues start rolling in. A company that has managed to sustain its operations and reach commercialization over 18 years has likely navigated many risks and challenges. Which is well-known around here. This experience in managing risks is reassuring, not alarming. Altogether, these are the long-term positive traits of KBLB that can't be denied. Skewed out of context, yes. Denied, no.

[want2retire]

Would you mind sharing with us the yearly shares diluted going back 10 years?

Keeping in mind the arranged shares for funding with Calm Seas and Yorkville. Those were pre-arranged and done in a way to limit the harm done to the share price and existing shareholders.

Let’s just focus on the company dumping shares into the market type dilution which is the one your fear mongering is based on.

Ok, let us have it (outside of the above referenced and any other arranged financing)!